Tags

Type your tag names separated by a space and hit enter

A review of the second-generation antihistamine ebastine for the treatment of allergic disorders.
Expert Opin Pharmacother. 2004 Aug; 5(8):1807-13.EO

Abstract

Ebastine is a once-daily, non-sedating, selective, long-acting, second-generation antihistamine. The use of ebastine is indicated in patients suffering from intermittent and persistent allergic rhinitis and chronic idiopathic urticaria. Ebastine 10 mg/day, appears as effective as other second-generation antihistamines, such as cetirizine and loratadine. Ebastine 20 mg/day is indicated in patients with moderate and severe allergic symptoms. No cardiovascular effects of ebastine are described, although there is a pharmacokinetic interaction when ketoconazole or macrolides are co-administered. Ebastine has no relevant effects on the psychomotor performance. Even with ebastine 20 mg/day skilled performance does not appear to be impaired. Furthermore, ebastine 5-10 and 2.5 mg, appears to be efficient and can be used safely in children 6-11 and 2-5 years of age, respectively. Ebastine appears to be a safe, effective and well-tolerated second-generation antihistamine in the treatment of allergic rhinitis and chronic idiopathic urticaria.

Authors+Show Affiliations

Department of Otorhinolaryngology, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium. paul.vancauwenberge@Ugent.beNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15264995

Citation

Van Cauwenberge, Paul, et al. "A Review of the Second-generation Antihistamine Ebastine for the Treatment of Allergic Disorders." Expert Opinion On Pharmacotherapy, vol. 5, no. 8, 2004, pp. 1807-13.
Van Cauwenberge P, De Belder T, Sys L. A review of the second-generation antihistamine ebastine for the treatment of allergic disorders. Expert Opin Pharmacother. 2004;5(8):1807-13.
Van Cauwenberge, P., De Belder, T., & Sys, L. (2004). A review of the second-generation antihistamine ebastine for the treatment of allergic disorders. Expert Opinion On Pharmacotherapy, 5(8), 1807-13.
Van Cauwenberge P, De Belder T, Sys L. A Review of the Second-generation Antihistamine Ebastine for the Treatment of Allergic Disorders. Expert Opin Pharmacother. 2004;5(8):1807-13. PubMed PMID: 15264995.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A review of the second-generation antihistamine ebastine for the treatment of allergic disorders. AU - Van Cauwenberge,Paul, AU - De Belder,Tine, AU - Sys,Lien, PY - 2004/7/22/pubmed PY - 2005/6/28/medline PY - 2004/7/22/entrez SP - 1807 EP - 13 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 5 IS - 8 N2 - Ebastine is a once-daily, non-sedating, selective, long-acting, second-generation antihistamine. The use of ebastine is indicated in patients suffering from intermittent and persistent allergic rhinitis and chronic idiopathic urticaria. Ebastine 10 mg/day, appears as effective as other second-generation antihistamines, such as cetirizine and loratadine. Ebastine 20 mg/day is indicated in patients with moderate and severe allergic symptoms. No cardiovascular effects of ebastine are described, although there is a pharmacokinetic interaction when ketoconazole or macrolides are co-administered. Ebastine has no relevant effects on the psychomotor performance. Even with ebastine 20 mg/day skilled performance does not appear to be impaired. Furthermore, ebastine 5-10 and 2.5 mg, appears to be efficient and can be used safely in children 6-11 and 2-5 years of age, respectively. Ebastine appears to be a safe, effective and well-tolerated second-generation antihistamine in the treatment of allergic rhinitis and chronic idiopathic urticaria. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/15264995/A_review_of_the_second_generation_antihistamine_ebastine_for_the_treatment_of_allergic_disorders_ L2 - https://www.tandfonline.com/doi/full/10.1517/14656566.5.8.1807 DB - PRIME DP - Unbound Medicine ER -